September 30- October 3, 2024, Discovery on Target

  1. Home
  2. Events
April 5- 10, 2024, AACR Conference
April 5, 2024
by admin aurigene

April 5- 10, 2024, AACR Conference

1) SMARCA 2/4 Degraders Relieve The Differentiation Block In AML via Changes In Chromatin Looping and Accessibility2) Paralogue Selectivity p300 Degraders Induce Synthetic Lethality in Pre-Clinical Models of CBP- Deficient
April 1- 4, 2024, Drug Discovery Chemistry
April 1, 2024
by admin aurigene

April 1- 4, 2024, Drug Discovery Chemistry

1) A Highly Differentiated Small Molecule Immune Checkpoint Inhibitor Dually Targeting PD-L1 And A2AR for Cancer Therapy2) Targeting CBM, A Tri Protein Signalling Hub, by Inhibition Of MALT1 for the
September 26, 2023
by admin aurigene

September 26-28, 2023, Discovery On Target

1) Targeting DDR1 Kinase to Address Tumor Dissemination, Immune Exclusion and Therapeutic Resistance2) Targeting CBP/P300 – Inhibition vs. Degradation for Potent Anti-Tumor Efficacy
June 8, 2023
by admin aurigene

June 8-11, 2023, European Hematology Association

1) A Phase 1, Open Label, Dose Escalation, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR-103 in Patients with Relapsed Advanced Malignancies (BHARAT-1)
April 14, 2023
by admin aurigene

April 14 – 19, 2023, AACR

1) Generation of Profound Anti-Tumor Immunity by AUR-109, A Spectrum-Selective Tyrosine Kinase Inhibitor, Either as a Single Agent or in Combination with Immune Checkpoint Inhibitors2) A Highly Differentiated A2AR Inhibitor
November 22, 2017
by Aurigene Tech Team

59th ASH Annual Meeting & Exposition

Aurigene will be participating at the annual American Society of Hematology (ASH) Conference  scheduled to be held in Atlanta, Georgia from December 9-12. More information about the conference can be